New Study from Caris Life Sciences Validates Optimal Sequencing in Informing Therapy Choices for Breast Cancer Subgroups
Caris Life Sciences (NASDAQ: CAI) has published a significant study in Breast Cancer Research comparing two antibody-drug conjugates for HER2-negative breast cancer treatment. The research analyzed over 4,000 patients to evaluate trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG).
Key findings revealed that T-DXd demonstrated superior effectiveness in hormone receptor (HR)-positive patients, while SG showed better results as first-line treatment for HR-negative and HER2-null tumors. For triple-negative breast cancer patients, both treatments showed comparable benefits, emphasizing the importance of personalized treatment approaches.
Caris Life Sciences (NASDAQ: CAI) ha pubblicato su Breast Cancer Research uno studio significativo che confronta due conjugati anticorpo鈥慺armaco per il trattamento del cancro al seno HER2-negativo. La ricerca ha analizzato oltre 4.000 pazienti per valutare trastuzumab deruxtecan (T-DXd) e sacituzumab govitecan (SG).
I risultati principali hanno mostrato che T-DXd ha dimostrato una maggiore efficacia nei pazienti con recettori ormonali (HR)-positivi, mentre SG ha dato risultati migliori come terapia di prima linea per i tumori HR-negativi e privi di espressione HER2 (HER2-null). Nei pazienti con carcinoma triplo negativo entrambe le terapie hanno offerto benefici comparabili, sottolineando l鈥檌mportanza di approcci terapeutici personalizzati.
Caris Life Sciences (NASDAQ: CAI) ha publicado en Breast Cancer Research un estudio importante que compara dos conjugados anticuerpo鈥慺谩rmaco para el tratamiento del c谩ncer de mama HER2鈥憂egativo. La investigaci贸n analiz贸 a m谩s de 4.000 pacientes para evaluar trastuzumab deruxtecan (T-DXd) y sacituzumab govitecan (SG).
Los hallazgos clave mostraron que T-DXd demostr贸 mayor eficacia en pacientes con receptores hormonales (HR) positivos, mientras que SG obtuvo mejores resultados como tratamiento de primera l铆nea en tumores HR negativos y con ausencia de expresi贸n HER2 (HER2-null). En pacientes con c谩ncer de mama triple negativo ambos tratamientos ofrecieron beneficios comparables, enfatizando la importancia de enfoques terap茅uticos personalizados.
Caris Life Sciences (NASDAQ: CAI)臧� Breast Cancer Research鞐� HER2 鞚岇劚 鞙犽癌鞎� 旃橂毳� 鞙勴暅 霊� 頃泊鈥戩暯氍� 瓴绊暕觳措ゼ 牍勱祼頃� 欷戩殧頃� 鞐瓣惮毳� 氚滍憸頄堨姷雼堧嫟. 鞚� 鞐瓣惮電� trastuzumab deruxtecan (T-DXd)瓿� sacituzumab govitecan (SG)毳� 韽夑皜頃橁赴 鞙勴暣 4,000氇� 鞚挫儊鞚� 頇橃瀽鞚� 攵勳劃頄堨姷雼堧嫟.
欤检殧 瓴瓣臣電� T-DXd臧� 順鸽ゴ氇� 靾橃毄觳�(HR) 鞏戩劚 頇橃瀽鞐愳劀 雿� 鞖办垬頃� 須臣毳� 氤挫澑 氚橂┐, SG電� HR 鞚岇劚 氚� HER2 氚滍槃 瓴办棳(HER2-null) 膦呾枒鞐愳劀 1彀� 旃橂搿� 雿� 膦嬱潃 瓴瓣臣毳� 雮橅儉雰堧嫟電� 鞝愳瀰雼堧嫟. 靷检鞚岇劚 鞙犽癌鞎� 頇橃瀽鞐愳劀電� 霊� 旃橂氩曥澊 鞙犾偓頃� 鞚挫爯鞚� 氤挫棳 臧滌澑 毵烄钉順� 旃橂 鞝戧芳鞚� 欷戩殧靹膘潉 臧曥“頄堨姷雼堧嫟.
Caris Life Sciences (NASDAQ: CAI) a publi茅 dans Breast Cancer Research une 茅tude importante comparant deux conjugu茅s anticorps鈥憁茅dicament pour le traitement du cancer du sein HER2鈥憂茅gatif. La recherche a analys茅 plus de 4 000 patientes afin d鈥櫭﹙aluer le trastuzumab deruxtecan (T鈥慏Xd) et le sacituzumab govitecan (SG).
Les principaux constats indiquent que T鈥慏Xd a montr茅 une sup茅riorit茅 d鈥檈fficacit茅 chez les patientes hormonod茅pendantes (r茅cepteurs hormonaux, HR鈥憄ositives), tandis que SG a donn茅 de meilleurs r茅sultats en premi猫re intention pour les tumeurs HR鈥憂茅gatives et sans expression HER2 (HER2鈥憂ull). Pour les patientes atteintes d鈥檜n cancer triple n茅gatif, les deux traitements ont apport茅 des b茅n茅fices comparables, soulignant l鈥檌mportance d鈥檃pproches th茅rapeutiques personnalis茅es.
Caris Life Sciences (NASDAQ: CAI) hat in Breast Cancer Research eine bedeutende Studie ver枚ffentlicht, die zwei Antik枚rper鈥慦irkstoff鈥慘onjugate zur Behandlung von HER2鈥憂egativem Brustkrebs vergleicht. Die Untersuchung wertete mehr als 4.000 Patientinnen und Patienten aus, um trastuzumab deruxtecan (T-DXd) und sacituzumab govitecan (SG) zu beurteilen.
Die wichtigsten Ergebnisse zeigen, dass T-DXd bei Hormonrezeptor (HR)-positiven Patientinnen eine 眉berlegene Wirksamkeit aufwies, w盲hrend SG als Erstlinientherapie bessere Resultate bei HR-negativen Tumoren ohne HER2鈥慐xpression (HER2-null) erzielte. Bei Patientinnen mit triple-negativem Brustkrebs waren die Vorteile beider Therapien vergleichbar, was die Bedeutung individualisierter Behandlungsans盲tze unterstreicht.
- Study of over 4,000 patients provides valuable real-world evidence for treatment decisions
- Research identifies optimal drug sequencing for different breast cancer subtypes
- Findings enable more personalized treatment strategies for breast cancer patients
- Demonstrates company's leadership in AI-driven precision medicine research
- No clear advantage in drug sequencing for some patient subgroups
- Lack of head-to-head clinical trials between the two drugs
Insights
Caris study reveals T-DXd benefits HR-positive breast cancer patients, while SG works better first for HR-negative/HER2-null cases, informing precision treatment decisions.
Caris Life Sciences has published valuable real-world evidence comparing two critical antibody-drug conjugates (ADCs) for breast cancer treatment. Their study of over 4,000 patients revealed important subtype-specific effectiveness patterns that could significantly impact clinical decision-making.
The findings demonstrate that trastuzumab deruxtecan (T-DXd) offers superior treatment duration for hormone receptor (HR)-positive patients across all HER2-negative groups compared to sacituzumab govitecan (SG). This is particularly noteworthy since HR-positive breast cancers represent approximately 70% of all breast cancer cases, making this finding relevant to the majority of breast cancer patients.
For patients with HR-negative and HER2-null tumors (often classified as triple-negative breast cancer), the study found that SG showed better results when used as the first-line ADC treatment. This sequencing information is crucial, as triple-negative breast cancer has historically had fewer targeted treatment options.
What makes this study particularly valuable is that it addresses a significant knowledge gap. No head-to-head clinical trials have directly compared these two frequently used ADCs in breast cancer treatment. By analyzing real-world data, Caris has provided clinicians with practical guidance on which agent might be most beneficial for specific patient subgroups.
The finding that both ADCs provide comparable benefits in triple-negative breast cancer patients further emphasizes the need for personalized treatment approaches based on comprehensive molecular profiling. This study exemplifies how real-world evidence can complement traditional clinical trials to optimize treatment sequencing strategies in oncology.
Caris demonstrates AI's clinical value by analyzing 4,000+ patient records to determine optimal cancer drug sequencing, showcasing real-world data's practical applications.
Caris Life Sciences has demonstrated a compelling application of AI and large-scale data analysis in precision oncology. By leveraging their extensive real-world database of over 4,000 patients, they've produced actionable clinical insights without requiring time-consuming and expensive randomized controlled trials.
What's particularly notable is how this represents AI's practical application in healthcare beyond theoretical potential. The company used its comprehensive molecular profiling capabilities (Whole Exome and Whole Transcriptome Sequencing) combined with advanced AI and machine learning algorithms to identify patient subgroups that respond differently to specific treatments.
This study showcases the emerging paradigm of data-driven clinical decision support. Traditional clinical trials typically have narrow inclusion criteria and may not represent the broader patient population. By analyzing real-world treatment outcomes across diverse patient groups, Caris has identified nuanced treatment response patterns that might not be evident in conventional trial designs.
The technological approach demonstrates the value of multimodal data integration - combining genomic information with clinical outcomes to create a more comprehensive understanding of treatment efficacy. This represents a significant advancement in how healthcare data can be utilized to inform personalized medicine approaches.
By translating complex molecular data into straightforward clinical guidance about drug sequencing, Caris is bridging the gap between advanced genomic science and practical clinical application. This approach could potentially reduce costly trial-and-error treatment attempts while improving patient outcomes through more precisely targeted therapy selection.
The study found that the cancer drug聽T-DXd聽worked better for patients whose tumors are聽hormone receptor (HR)-positive, helping them stay on treatment longer than those taking聽SG, across all HER2-negative groups. However, for patients with聽HR-negative and HER2-null tumors,聽SG聽showed better results when used as the first treatment. For other patient groups, there was聽no clear advantage聽to starting with one drug over the other.
"With the industry absence of head-to-head trials between the two most commonly used ADCs in breast cancer, real-world evidence remains our best tool to explore key questions around treatment scheduling and comparative effectiveness in similar patient populations," said , Caris EVP and Chief Medical Officer.
Caris' real-world database drew from over 4,000 patients to uncover key differences that have the potential to assist clinicians in choosing treatment options to improve patient care. Additionally, results concluded that T-DXd and SG provided comparable benefits in patients with triple-negative breast cancer, highlighting the need for personalized treatment strategies based on tumor subtype.
"This study highlights the power of Caris to turn vast, real-world data into clinically actionable insights," said , President of Caris. "Caris is leading the charge in precision medicine by combining advanced AI and vast real-world data to illuminate paths toward more personalized care. It's not just innovation; it's a reimagining of how science meets treatment."
The publication can be viewed in its entirety on the Caris Life Sciences website.
About Caris Life Sciences
Caris Life Sciences庐鈥�(Caris) is a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer that is actively developing and commercializing innovative solutions to transform healthcare. Through comprehensive molecular profiling (Whole Exome and Whole Transcriptome Sequencing) and the application of advanced AI and machine learning algorithms at scale, Caris has created the large-scale, multimodal clinico-genomic database and computing capability needed to analyze and further unravel the molecular complexity of disease. This convergence of next-generation sequencing, AI and machine learning technologies, and high-performance computing provides a differentiated platform to develop the latest generation of advanced precision medicine diagnostic solutions for early detection, diagnosis, monitoring, therapy selection and drug development.
Caris was founded with the belief and vision that combining a vast set of consistently generated molecular information with robust data-driven insights could realize the potential of precision medicine for patients. Headquartered in
Forward Looking Statements
This press release contains forward-looking statements, within the meaning of the federal securities laws, about Caris Life Sciences and its business. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases forward-looking statements can be identified by words such as "may," "will," "should," "would," "expect," "plan," "anticipate," "could," "intend," "target," "project," "potential," "contemplate," "believe," "estimate," "predict," "potential," "supports" or "continue" or similar expressions.
You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in these forward-looking statements are reasonable based on information currently available to us, we cannot guarantee that the future results, discoveries, levels of activity, performance or events and circumstances reflected in forward-looking statements will be achieved or occur. Forward-looking statements involve known and unknown risks and uncertainties, some of which are beyond our control. Risks and uncertainties that could cause our actual results to differ materially from those indicated or implied by the forward-looking statements in this press release include, among other things: developments in the precision oncology industry; future financial performance, results of operations or other operational results or metrics; development, validation and timing of future solutions; the rapidly evolving competitive environment in which we operate; third-party payer reimbursement and coverage decisions; our ability to protect and enhance our intellectual property; regulatory requirements, decisions or approvals (including the timing and conditions thereof) related to our solutions; our compliance with laws and regulations; and our ability to hire and retain key personnel as well as risks, uncertainties, and other factors described in the section titled "Risk Factors" and elsewhere in the prospectus for our initial public offering filed with the Securities and Exchange Commission on June 20, 2025, and in our other filings we make with the SEC from time to time. We undertake no obligation to update any forward-looking statements to reflect changes in events, circumstances or our beliefs after the date of this press release, except as required by law.
Caris Life Sciences Media:
Corporate Communications
[email protected]
214.294.5606
View original content to download multimedia:
SOURCE Caris Life Sciences
FAQ
What are the key findings of Caris Life Sciences' breast cancer treatment study?
How many patients were included in Caris Life Sciences' breast cancer study?
What is the significance of Caris Life Sciences' breast cancer research?
How does Caris Life Sciences use AI in their cancer research?
Which breast cancer treatments did the Caris study compare?
